Backs FY25 adjusted EBITDA view $135M-$156MEvolent Health (EVH) announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-$165M. John Johnson, Evolent’s CFO, noted, “We are pleased to see oncology trend remaining below forecast now for the first two thirds of the quarter. We remain confident in meeting or beating the expectations we set for the 2nd quarter and full year. If these trends continue through June, we would anticipate being in the top half of our range for Q2 Adjusted EBITDA.” The company also announced it signed a commitment letter with Ares Management Credit funds, securing the option to borrow additional non-dilutive capital, if needed, to address its 2025 Convertible Notes while leaving incremental working capital on its balance sheet to support Evolent’s accelerating organic growth pipeline.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health Restructures Board Committees in June 2025
- Evolent Health Reaffirms 2025 Revenue and EBITDA Guidance
- Evolent Health: Buy Rating Affirmed on Positive Financial Adjustments and Growth Outlook
- Evolent Health Inc. Earnings Call Highlights Growth and Expansion
- Evolent Health price target raised to $15 from $14 at UBS
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue